					ATTORNEY DOCKET	APPLICATION NO.		
!NI	FORM	ATION DISCLOS						
(37 C.F.R. 1.56, 1.97, and 1.98)					20404 4000	20/25		
(In eggs					23164-1003	08/853,292		
EB O B IO					APPLICANT(S)			
					Tovey, Michael G.			
SHEET 1 OF 1					FILING DATE	GROUP		
					May 9, 1997	1801		
U.S. PATENT DOCUMENTS								
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)		NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)	
FOREIGN PATENT DOCUMENTS								
† EX'R	*					00/01	TRANSLATION	
INITIAL	REF. #					ce/sut	(YES/NO)	
111	1	EP 578 823 A1	01/19/94		EPO		NO	
OTHER DOCUMENTS								
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)						
M	2	Kaido, T.J., "Intranasal administration of IFN-α/β inhibits the development of visceral tumor metastases," Journal of Interferon and Cytokine Research, 17:31-36 (1997).						
W	3	Yoshino, S., "The preventive effect of oral administration of type 1 interferon on collagen-induced arthritis in rats," <i>Experimental and Molecular Pathology</i> , 62:123-130 (1995).						
	•							
		· · · · · · · · · · · · · · · · · · ·						
EXAMINER'S SIGNATURE- DATE CONSIDERED 12 Apr 55								
+ EVAMINED. Initial if reference is considered, whether or not citation is in conformance with MDED 600. Line through citation if not in								

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant*.

^{*} If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).